Hidden Malignancy: Ileocecal Intussusception as an Atypical First Presentation of Diffuse Large B-cell Lymphoma in Adulthood.
1/5 보강
Intussusception is predominantly a pediatric condition, with only about 5 % of all intussusception cases occurring in adults with primary intestinal lymphomas comprising 1 %-4 % of gastrointestinal ma
APA
Harisinghani K, Adrejiya P, et al. (2026). Hidden Malignancy: Ileocecal Intussusception as an Atypical First Presentation of Diffuse Large B-cell Lymphoma in Adulthood.. Journal of community hospital internal medicine perspectives, 16(1), 56-59. https://doi.org/10.55729/2000-9666.1567
MLA
Harisinghani K, et al.. "Hidden Malignancy: Ileocecal Intussusception as an Atypical First Presentation of Diffuse Large B-cell Lymphoma in Adulthood.." Journal of community hospital internal medicine perspectives, vol. 16, no. 1, 2026, pp. 56-59.
PMID
41809228 ↗
Abstract 한글 요약
Intussusception is predominantly a pediatric condition, with only about 5 % of all intussusception cases occurring in adults with primary intestinal lymphomas comprising 1 %-4 % of gastrointestinal malignancies, 90 % of which are B-cell non-Hodgkin lymphomas (NHL). Diffuse large B-cell lymphoma (DLBCL), the most common subtype of NHL, often leads to intussusception without classical B symptoms. We present the case of a 33-year-old male with ileocolonic intussusception caused by a 4.8 × 5.3 × 5.5 cm enhancing mass. Histopathology and FISH confirmed DLBCL without MYC, BCL2, or BCL6 rearrangements, ruling out double- or triple-hit lymphoma. Following a right ileo-colectomy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy was initiated. This case underscores the role of malignancy in intussusception and highlights the importance of timely diagnosis and management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.
- Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
- Exploring Gallium(III) Complexes as Emerging Therapeutic Candidates for Breast Cancer.
- Prognostic Value of the CALLY Index in Diffuse Large B-Cell Lymphoma: Linking Inflammation, Nutrition, and Tumor Biology.
- Survival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma.